An integrated database for cancer molecular targeted thearpies

Help Center

The integrated database for cancer molecular-targeted therapies (CMTTdb) v1.0 is a database providing information from the clinical trials of molecularly targeted cancer therapies. It is of benefit to clinicians, since the database illustrates useful information about design, efficacy and safety results, and clinical implications, as well as information behind the targeted agents, target, and cancer types. We offer easier search and handy search tools on the CMTTdb site to facilitate finding useful information about molecularly targeted cancer therapies and their combinatorial modes. We also provide crosslinks to many other important databases. If a cancer patient with available mutational information went to see an oncologist, the doctor might find useful information through our database about the patient's cancer subtype, whether the patient has certain driver mutations, which kinds of targeted agents are suitable, and how to combine all the different types of cancer therapies. The doctor may even update their knowledgebase of certain cancer therapies.

There are various ways to access information within the database, including:

  1. Access the Quick search, then do one of the following:
    • Select Agent, enter "gefitinib", and click Submit. This will provide information about synonymous, drug status for certain diseases, drug classification, the target and the pathway they control in the KEGG database and WikiPathway database.
    • Select database ID, enter an ID Number, then click Submit. Information about the applicable clinical trial design and its related results is then displayed. If you require more information on the study, you can find the reference by PMID and get the full article.
    • Select cancer type, then click Submit. The ICD number crosslinks to the up-to-date database, which will be beneficial to clinicians.
    • Select target, enter the appropriate keywords, then click Submit. A short description of the target, the year it was introduced, and hyperlinks to MeSH and TTD databases are returned. The system will automatically return the "Query result"
  2. Click Browse database to get an overview of the database. From the "Agent", "target" and "cancer type" with unique database ID, click View for detailed information on the target or agent of interest.

The "detailed information" page is composed of three parts: Reference, Design, and Results. The Reference section contains the title, authors, journal and PMID of the article. The Design section provides the clinical trial ID, related agent, its target, cancer type and subtype, key patients' features, biomarker and biomarker analysis, therapy modality and detailed treatment information. The Results section contains the important clinical parameters related to efficacy and safety (MTD, DLT, ORR, PFS, OS, etc.).

The detailed information page requires the following supplemental information to correctly interpret the information:

  1. "Therapy type" refers to whether the clinical trial or study was conducted in the mode of targeted-agents monotherapy or combination therapy with other approaches, such as chemotherapy, radiation therapy, bi-targeted therapy, immunotherapy, endocrine therapy, and transcatheter arterial chemoembolization.
  2. "Therapeutic combination type" refers to specific combination modalities. Here we use Roman numerals to stand for different modes, as listed below:
    • Bi-targeted therapy
    • Targeted therapy + chemotherapy
    • Targeted therapy + chemoradiation therapy
    • Targeted therapy + radiation therapy
    • Targeted therapy + surgery + chemotherapy
    • Targeted therapy + surgery + chemoradiation therapy
    • Multi-targeted therapy
    • Immune checkpoint inhibition + chemotherapy
    • Bi-targeted therapy + immune checkpoint inhibition
    • Targeted therapy + endocrine therapy + radiation therapy
    • Immune checkpoint inhibition + vaccination therapy
    • Immune checkpoint inhibition + radiation therapy
    • Bi-targeted therapy + chemotherapy
    • Bi-targeted therapy + chemoradiation therapy
    • Targeted therapy + immune modulation
    • Targeted therapy + transcatheter arterial chemoembolization
    • Targeted therapy + endocrine therapy
    • Targeted therapy + endocrine therapy + chemotherapy
  3. "Therapeutic combination content" refers to the specific details of the therapy.
  4. "Treatment information" explains how to administer the drugs or therapeutic approaches.
    1. CMTTdb v1.0 provides key features for patient selection, biomarkers for molecular stratification and treatment allocation purposes, and the results of primary and secondary end-points in which clinicians are interested.

      CMTTdb v1.0 also provides useful crosslinks to other relevant databases. Our database is well suited for clinicians, who can also update their own knowledge-bases by searching our database and viewing the applicable crosslinked up-to-date databases. Through the Therapeutic Target Database, users can access further details on the target 3D structure, sequence, function, nomenclature, drug/ligand binding properties, etc. Via KEGG or Wikipathway databases, users can get a vivid glimpse of the pathways involved.